serogroup b meningococcal vaccine (Trumenba) Report issue

Vaccine Approved FDA
AACT

Active Ingredient History

NOW
  • Now

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

bivalent rlp2086 | meningococcal b vaccine | mnb rlp2086 | mnb rlp8026 | neisseria meningitidis serogroup b fhbp (recombinant lipidated fhbp (factor h binding protein)) subfamily a; neisseria meningitidis serogroup b fhbp (recombinant lipidated fhbp (factor h binding protein)) subfamily b | recombinant meningococcal b vaccine | rlp2086 | serogroup b meningococcal vaccine | trumenba vaccine

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (1)


 

Meningococcal Vaccines (approved 2014)

Experimental Indications - Clinical Trial Phases 1-4 (10)


 

Drugs, Investigational (Phase 2)

Gonorrhea (Phase 4)

Healthy Volunteers (Phase 4)

Meninges (Phase 2)

Meningitis (Phase 2)

Meningitis, Meningococcal (Phase 3)

Meningococcal Infections (Phase 4)

Meningococcal Vaccines (Phase 4)

Splenectomy (Phase 3)

Vaccines (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 35
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue